Last reviewed · How we verify
NCT04696913
Does COVID-19 Infection Increase the Risk of Pulmonary Embolism?
trial testing Exposure: Positive COVID-19 infection in Covid19 in 347 participants. Status unknown.
22 November 2021
Quick facts
| Lead sponsor | University of Aberdeen |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 347 |
| Start date | 1 January 2021 |
| Primary completion | 22 November 2021 |
| Estimated completion | 22 November 2021 |
Drugs / interventions tested
- Exposure: Positive COVID-19 infection
- Exposure: Negative COVID-19 infection
Conditions studied
- Covid19 — all drugs for Covid19 →
- Pulmonary Embolism — all drugs for Pulmonary Embolism →
Sponsor
University of Aberdeen
Who can join
16 and older, any sex, with Covid19 or Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The World Health Organization (WHO) declared the 2019 novel coronavirus (COVID-19) a pandemic on March 11, 2020. As of 19 July 2020, there have been 14.3 million confirmed cases and over 600,000 confirmed deaths. Up to 14% of infected patients develop interstitial pneumonia, which may evolve to acute respiratory distress syndrome. COVID-19 associated pulmonary arterial microthrombosis and coagulopathy has prompted physicians to implicate pulmonary embolism (PE) as a potential cause for acute respiratory deterioration. Literature review reveals few studies of varying size, quality and design. Recent meta-analysis reports venous thromboembolism in approximately 20% of COVID-19 patients. There has yet to be a case-controlled study which proves and quantifies the associated between COVID-19 and PE.Confirming and quantifying this association has numerous clinical implications for the treatment of critically unwell patients with COVID-19 infection. For example, clinicians will be more inclined to investigate and treat sudden deteriorations with the knowledge that pulmonary embolism is the commonest cause for said deteriorations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04696913
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other University of Aberdeen trials
Trials by the same sponsor.
- NCT07070765 — Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity · NA · not yet recruiting
- NCT07065383 — Rebalancing the Fat Content of the Heart and Muscles · NA · recruiting
- NCT06735573 — Protein, Sarcopenic Obesity, and COPD · not yet recruiting
- NCT06714656 — Drivers and Barriers for Adopting Healthy and Sustainable Food Swaps in Young · NA · recruiting
- NCT06721312 — Continuous Heart Rate Variability Monitoring in Doctors; Understanding Patterns of Stress and Recovery and Their Relatio · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04696913 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Aberdeen
- Last refreshed: 6 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04696913.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing